Table 1.

Clinical features of published case reports of adverse effects from mefloquine, and their possible relation to liver and thyroid pathology

	Prophylaxis case reports (N = 328)	Treatment case reports (N = 188)
Number (%) of reports very likely liver related	75/328(23)	85/188(45)
Number (%) of reports plausibly but debatably liver related	102/328(31)	29/188(15)
Number (%) of reports plausibly thyroid related	51/328(16)	26/188(14)
Probably unrelated to liver or thyroid	100/328(30)	48/188(26)
Median dose (range) of mefloquine taken (mg)	750(250–8750)	1250(150–5250)
Median duration (range) of adverse effects (days)	16(1–550)	4(1–300)